Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2020

View Archived Issues

"Don't Eat Me" signal doubles as "Don't Find Me"

Oral tebipenem demonstrates noninferiority to i.v. ertapenem in cUTI and AP

First patient enrolled in phase I study of AIC-100 CAR T cells for thyroid cancer

Aveni Foundation initiates phase I/II study of DeltaRex-G for COVID-19

Phase III study of 18F-APN-1607 tau PET tracer approved in China

Novartis and Molecular Partners collaborate to develop two DARPin therapies against COVID-19

Six months of therapy completed in low-dose cohort of phase I/II brain cancer study of NOX-A12

Lynk Pharmaceuticals discloses new JAK inhibitors

Zhuhai Yufan Biotechnologies patents CDK inhibitors

Qilu Regor Therapeutics identifies tyrosine kinase inhibitors

Accutar Biotechnology synthesizes new PROTACs for cancer

University of Massachusetts presents factor H vectors

First patient dosed in dose-expansion evaluating DSP-7888 plus pembrolizumab in ovarian cancer

MEDI-3902 may reduce incidence of P. aeruginosa pneumonia in specific populations

Initiation of phase I/II GOBLET study of pelareorep plus atezolizumab in GI cancers

Daewoong's sustained-release niclosamide shows efficacy against both COVID-19 and seasonal flu

Xoma earns milestone payment from Novartis as NIS-793 enters phase II development

Astellas Pharma's pneumococcal vaccine demonstrates highly immunogenic properties

"Foundational" research shows early gene therapy prevents Angelman syndrome

MediWound completes enrollment in phase II pediatric study of NexoBrid

First results from IPAX-1 clinical trial for GBM

FDA gives positive pre-IND response for clinical development of AS-1411 for COVID-19

CStone, LegoChem enter global licensing agreement for new antibody-drug conjugate

PeproMene submits IND for PMB-101 for the treatment of B-ALL

Insignis, HLK Pharmacin receive FDA IND clearance for phase I trial of IN-001 in anaphylaxis

Topline results from phase II AURORA trial of avacopan reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...